The FDA has approved rebisufligene etisparvovec-hopf (Fayuvi), the first treatment designed to alter the course of mucopolysaccharidosis type IIIA.
|Articles|November 10, 2022
Camber Pharmaceuticals Launches Generic Esbriet®
Advertisement
Camber Pharmaceuticals is pleased to announce the addition of Pirfenidone Tablets to its current portfolio.
Pirfenidone Tablets are indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
Pirfenidone Tablets from Camber are available in two strengths:
- 267 mg in 3 pack/ 90 count bottles (270 count total)
- 801 mg strength in 90 count bottles
To find out more about Pirfenidone Tablets please visit
###
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.
SOURCE: Camber Pharmaceuticals
Advertisement
Related to this article
This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
The approval is supported by data from the phase 3 FINE-ONE clinical trial.
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
3
From Reactive to Proactive: AI's Role in Modern Pharmacy Safety
4
Trial Ended Early When Venetoclax Plus DA-EPOCH-R Did Not Improve Outcomes in Double-Hit Lymphoma
5